TESARO Partnership

Under our immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize antibodies generated using our SHM platform consisting of the following antibody product candidates:

Anti-PD-1 Monospecific Antagonist Antibody (TSR-042): Phase 1 clinical trial dosing initiated in the first quarter of 2016 subsequent to the acceptance of a U.S. FDA IND, expect dose and schedule by year-end 2016, finalize registration strategy and initiate a registration program in the first half of 2017;

Anti-TIM-3 Monospecific Antagonist Antibody (TSR-022): Phase 1 clinical trial dosing initiated in the third quarter of 2016 subsequent to the acceptance of a U.S. FDA IND, expect initiation of an anti-PD-1 combination trial in the first half of 2017;

Anti-LAG-3 Monospecific Antagonist Antibody (TSR-033): currently in preclinical development, expect the initiation of a Phase 1 trial in the first half of 2017;

Anti-PD-1/TIM-3 Bispecific Antagonist Antibody: currently in lead selection process;

Anti-PD-1/LAG-3 Bispecific Antagonist Antibody: currently in lead selection process; and

Undisclosed Bispecific Antagonist Antibody: currently in lead selection process.

To access scientific publications on this topic, please click here.